Metformin drives HIF-1α–mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple-negative breast cancer
Cancer Immunology, Immunotherapy · 2026
DOI: 10.1007/s00262-026-04351-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Xuping Qin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China. Hauptthemen laut MEDLINE: Metformin, Triple Negative Breast Neoplasms, Hypoxia-Inducible Factor 1, alpha Subunit, Receptors, Antigen, T-Cell, gamma-delta. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) lacks effective targeted treatments, rendering γδ T cell immunotherapy a promising therapeutic strategy. However, the function of these immune cells is often limited by exhaustion and immunosuppression. This study investigated whether metformin can enhance γδ T cell-mediated immunity against TNBC. Results demonstrated that metformin increased the cytotoxicity, proliferation, and cytokine production of γδ T cells while reducing their exhaustion markers. It differentially modulated cellular metabolism by enhancing oxidative phosphorylation (OXPHOS) and glycolysis in γδ T cells while suppressing these pathways in cancer cells through AMPK-HIF1-α signaling. Metformin also upregulated stress ligands on tumor cells, thereby improving immune recognition. In chemoresistant models, metformin restored γδ T cell function. Clinical data further showed that high AMPK activity and increased γδ T cell infiltration were associated with improved patient survival. These findings indicate that metformin remodels immunometabolism and enhances tumor immunogenicity, supporting its potential as a combinatory agent in γδ T cell-based immunotherapy for TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China.
- Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China.
- Department of Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China. wangxw83@mail.sysu.edu.cn.
- Department of Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China. longjt2@mail.sysu.edu.cn.
Förderung
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Qin, X., Zhong, H., Liu, M., Yu, T., Ma, R., Zhou, Y., Chen, J., Liu, F., Wang, X., & Long, J. (2026). Metformin drives HIF-1α–mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple-negative breast cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04351-w
Vancouver
Qin X, Zhong H, Liu M, Yu T, Ma R, Zhou Y, et al. Metformin drives HIF-1α–mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple-negative breast cancer. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04351-w
BibTeX
@article{Qin2026,
author = {Qin, Xuping and Zhong, Haowen and Liu, Meize and Yu, Tiantian and Ma, Rong and Zhou, Ying and Chen, Jingyu and Liu, Fen and Wang, Xiwei and Long, Jianting},
title = {Metformin drives HIF-1α–mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple-negative breast cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-026-04351-w}
}
EUVIMED